Cargando…

A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon‐alpha2

BACKGROUND: Conventional cytoreductive therapy for patients with chronic Philadelphia‐negative myeloproliferative neoplasms (MPNs) includes hydroxyurea (HU), interferon‐alpha2 (IFN), and anagrelide. HU is worldwide the most used cytoreductive agent, which lowers elevated blood cell counts within day...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dam, Marc J. B., Pedersen, Rasmus K., Knudsen, Trine A., Andersen, Morten, Ellervik, Christina, Larsen, Morten Kranker, Kjær, Lasse, Skov, Vibe, Hasselbalch, Hans C., Ottesen, Johnny T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972145/ https://www.ncbi.nlm.nih.gov/pubmed/36254099 http://dx.doi.org/10.1002/cam4.5285

Ejemplares similares

Mathematical Modeling of MPNs Offers Understanding and Decision Support for Personalized Treatment
por: Ottesen, Johnny T., et al.
Publicado: (2020)

Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development
por: Andersen, Morten, et al.
Publicado: (2017)

Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms
por: Skov, Vibe, et al.
Publicado: (2022)

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
por: Hasselbalch, Hans, et al.
Publicado: (2022)

Data‐driven analysis of JAK2V617F kinetics during interferon‐alpha2 treatment of patients with polycythemia vera and related neoplasms
por: Pedersen, Rasmus K., et al.
Publicado: (2020)

JAK2V617F mutation is highly prevalent in patients with ischemic stroke: a case-control study
por: Kristiansen, Marie Hvelplund, et al.
Publicado: (2023)

HSC Niche Dynamics in Regeneration, Pre-malignancy, and Cancer: Insights From Mathematical Modeling
por: Pedersen, Rasmus Kristoffer, et al.
Publicado: (2022)

Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis
por: Kjær, Lasse, et al.
Publicado: (2023)

Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms
por: Hasselbalch, Hans Carl, et al.
Publicado: (2023)

Patients with MPNs and retinal drusen show signs of complement system dysregulation and a high degree of chronic low-grade inflammation
por: Liisborg, Charlotte, et al.
Publicado: (2021)

Clonal haematopoiesis of indeterminate potential and impaired kidney function—A Danish general population study with 11 years follow‐up
por: Larsen, Morten K., et al.
Publicado: (2022)

Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow
por: Holmström, Morten Orebo, et al.
Publicado: (2023)

Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia
por: Eickhardt-Dalbøge, Christina Schjellerup, et al.
Publicado: (2023)

The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment
por: Eickhardt-Dalbøge, Christina Schjellerup, et al.
Publicado: (2022)

Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses
por: Skov, Vibe
Publicado: (2020)

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses
por: Knudsen, Trine Alma, et al.
Publicado: (2022)

Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer’s disease: evidences and perspectives
por: Hasselbalch, Hans C., et al.
Publicado: (2020)

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment
por: Kjær, Lasse, et al.
Publicado: (2016)

MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives
por: Hasselbalch, Hans Carl, et al.
Publicado: (2015)

Potential of Immunotherapies in Treating Hematological Cancer-Infection Comorbidities—A Mathematical Modelling Approach
por: Ottesen, Johnny T., et al.
Publicado: (2021)

Whole Blood Transcriptional Profiling Reveals Deregulation of Oxidative and Antioxidative Defence Genes in Myelofibrosis and Related Neoplasms. Potential Implications of Downregulation of Nrf2 for Genomic Instability and Disease Progression
por: Hasselbalch, Hans Carl, et al.
Publicado: (2014)

Cytokine Profiling as a Novel Complementary Tool to Predict Prognosis in MPNs?
por: Hasselbalch, Hans C.
Publicado: (2020)

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
por: Sørensen, Anders Lindholm, et al.
Publicado: (2020)

COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon
por: Hasselbalch, H.C., et al.
Publicado: (2021)

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals
por: Holmström, Morten O., et al.
Publicado: (2019)

Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis
por: Mikkelsen, Stine Ulrik, et al.
Publicado: (2018)

Retinal drusen in patients with chronic myeloproliferative blood cancers are associated with an increased proportion of senescent T cells and signs of an aging immune system
por: Liisborg, Charlotte, et al.
Publicado: (2021)

Lower CXCR3 expression in both patients with neovascular AMD and advanced stages of chronic myeloproliferative blood cancers
por: Liisborg, Charlotte, et al.
Publicado: (2022)

Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study
por: Sørensen, Anders L., et al.
Publicado: (2021)

Serum levels of IL-4, IL-13 and IL-33 in patients with age-related macular degeneration and myeloproliferative neoplasms
por: Gotfredsen, Kathrine, et al.
Publicado: (2023)

Aging, Inflammation, and Comorbidity in Cancers—A General In Silico Study Exemplified by Myeloproliferative Malignancies
por: Ottesen, Johnny T., et al.
Publicado: (2023)

Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression
por: Carnaz Simões, Ana Micaela, et al.
Publicado: (2022)

Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression
por: Simões, Ana Micaela Carnaz, et al.
Publicado: (2022)

Transcriptional Profiling of Whole Blood Identifies a Unique 5-Gene Signature for Myelofibrosis and Imminent Myelofibrosis Transformation
por: Hasselbalch, Hans Carl, et al.
Publicado: (2014)

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial
por: Grauslund, Jacob Handlos, et al.
Publicado: (2023)

Biology and therapeutic targeting of molecular mechanisms in MPNs
por: How, Joan, et al.
Publicado: (2023)

Smoking is associated with increased risk of myeloproliferative neoplasms: A general population‐based cohort study
por: Pedersen, Kasper M., et al.
Publicado: (2018)

A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis
por: Skov, Vibe, et al.
Publicado: (2016)

A tale of two alleles: TP53 and transformation in MPNs
por: Brierley, Charlotte, et al.
Publicado: (2022)

Magnetic Peripheral Nerve Stimulation (mPNS) for Chronic Pain
por: Bedder, Marshall, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fthgf1mpp2fjm82o3ihlkf6fhn